Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model
June 27, 2024 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., June 27, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company” (NASDAQ:VVOS), a leading medical device and technology company specializing in the development...
Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance
June 12, 2024 07:30 ET
|
Vivos Therapeutics, Inc
Alliance with Sleep Treatment Provider in Colorado Marks Critical Pivot in Vivos’ Marketing and Distribution Model Aimed at Enhancing Revenue Streams and Potential Profit Private Placement Investment...
Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update
May 14, 2024 16:05 ET
|
Vivos Therapeutics, Inc
Vivos Expanding its Revenue Generating InitiativesAs Operating Expenses Decrease 22%, Representing Seven Consecutive Quarters ofYear Over Year Improvement Due to Successful Cost Cutting Initiatives ...
Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call
May 14, 2024 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development...
Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
April 09, 2024 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the...
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
March 28, 2024 16:05 ET
|
Vivos Therapeutics, Inc
Positive Business Momentum and Sales Pipeline Growth Following FDA 510(k) Clearance of Vivos’ Proprietary Oral Medical Devices to Treat Severe Obstructive Sleep Apnea Annual Operating Expenses...
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call
March 28, 2024 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the...
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds
February 15, 2024 08:00 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the...
Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities
February 06, 2024 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development...
Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSA
January 08, 2024 07:30 ET
|
Vivos Therapeutics, Inc
Vivos Therapeutics is seeing positive preliminary metrics regarding FDA 510(k) clearance of its CARE oral medical devices to treat severe OSA.